Intravitreal Methotrexate in the Prevention of Recurrent RD After PVR

Scott Walter, MD

Show Description +

Scott Walter, MD, discusses the efficacy of a treat-and-extend protocol for intravitreal methotrexate for the prevention of recurrent retinal detachment in patients who have had proliferative vitreoretinopathy.

Posted: 7/28/2020

Keywords:

Proliferative Vitreoretinopathy (PVR)

•

Retinal detachment, RD

•

retina-meeting-recap

Up Next

Using 3-Month Outcomes to Predict Long-Term Vision Outcomes in Wet AMD Patients

Paul Hahn, MD, PhD

AU-011 for Choroidal Melanoma

Ivana Kim, MD

Mathematical Model for Outcomes in CEDAR and SEQUOIA

Peter Kaiser, MD

Demographics in PANORAMA Patients

Nathan Steinle, MD

Sustained Release Fluocinolone Acetonide for Uveitis

Dilraj Grewal, MD

MVP: A New Surgical Tool

Carl C. Awh, MD

PDR Treatment Patterns

Jeremiah Brown Jr, MD, MS

Next-Generation Intraoperative OCT

Lejla Vajzovic, MD

RGX-314: Phase 1/2a Data

Arshad Khanani, MD

Back to All Videos

Intravitreal Methotrexate in the Prevention of Recurrent RD After PVR

Scott Walter, MD

Posted: 7/28/2020

Keywords:

Proliferative Vitreoretinopathy (PVR)

•

Retinal detachment, RD

•

retina-meeting-recap

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

Intravitreal Methotrexate in the Prevention of Recurrent RD After PVR

Up Next

Intravitreal Methotrexate in the Prevention of Recurrent RD After PVR

More From ASRS: 2020 Coverage